LTR Pharma is a Clinical Stage Biopharmaceutical Company
Erectile Dysfunction (ED) is a condition in which you are unable to get or keep an erection firm enough for satisfactory sexual intercourse. ED can be a short-term or long-term problem.
SPONTAN® provides on demand delivery and faster effect. A lower dose provides less systematic exposure and reduced side effects
LTR Pharma is commercialising a ‘First in Class’ rapid treatment for Erectile Dysfunction (ED) SPONTAN® with fast-track US NDA Filing within two years
worldwide expected cases by 2025
minute effectiveness
projected global market value 2024
ED is a serious and common medical problem with significant impacts to both physical and psychological health
ED has been identified as a major factor in relationship breakdown (20%). The worldwide prevalence doubled in the last 30 years and is expected to increase to 322 million in 2025.
This week, Professor Chung shares insights on the common misconceptions about the lived experience of Erectile Dysfunction (ED); myths in relation to treatment of ED, his professional views on the particular issues around the context of men’s sexual health and why he believes SPONTAN® is being welcomed as a potential
LTR Pharma has today announced it has entered into a Comprehensive Co-Development Agreement with Aptar Pharma for SPONTAN® for global markets. APTAR is a global leader in the design and manufacturing of a broad range of drug and consumer product dosing, dispensing and protection technologies. APTAR has substantial FDA regulatory
LTR Pharma has been featured in The West Australian, in an article titled ‘A Treatment on the Up’ by business journalist Cheyanne Enciso highlighting the significance of Australian patients being the first in the world to access to a PDE5 nasal-spray treatment for erectile dysfunction, SPONTAN®. The article includes comments
9/204 Alice Street, Brisbane QLD 4000
Phone: 1800 519 711